Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma (Nasdaq: ZEAL) announces participation in the LifeSci Nordic Biotech Summit on June 29, 2021. Senior management will present virtually at 1:30 p.m. ET / 7:30 p.m. CET. A live webcast will be accessible on the Company's website under the 'Events & Presentations' section and will be archived post-event. Zealand specializes in developing innovative peptide-based medicines, having advanced over 10 drug candidates into clinical development, with two currently on the market.
Zealand Pharma (Nasdaq: ZEAL) announced its participation at the 81st Annual American Diabetes Association Scientific Sessions, presenting six abstracts on Zegalogue® (dasiglucagon) from June 25-29, 2021. This includes one oral presentation demonstrating dasiglucagon's efficacy in treating severe hypoglycemia in diabetes patients aged six and above, following its FDA approval on March 22, 2021. The company aims to advance treatment options for those affected by severe hypoglycemia, showcasing its commitment to diabetes care.
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions in its shares by persons in managerial roles and their associates, as per corporate governance guidelines. The company focuses on innovative peptide-based medicines, with a pipeline featuring three late-stage drug candidates. Zealand's notable products include V-Go® and Zegalogue®. The press release emphasizes the company's commitment to enhancing patient care through peptide therapeutics, supported by collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.
On June 10, 2021, Zealand Pharma announced a capital increase of DKK 89,996 by issuing 89,996 new shares due to the exercise of employee warrants. The exercise price was DKK 135.30 for 4,395 shares and DKK 100.80 for 85,601 shares, resulting in total proceeds of DKK 9,223,224.30. The new shares will be listed on Nasdaq Copenhagen, raising the share capital to DKK 43,541,838. This move is part of Zealand Pharma's employee incentive programs, providing shares with voting rights at general meetings.
Zealand Pharma (Nasdaq: ZEAL) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. Members of the senior management team are scheduled to present virtually at 9:40 a.m. ET / 3:40 p.m. CET. A live webcast will be available on the Company's website under 'Events & Presentations,' with an archived replay following the event. Zealand focuses on peptide-based medicines and has a strong pipeline, including the recently approved Zegalogue for severe hypoglycemia in diabetes patients.
Boehringer Ingelheim and Zealand Pharma (Nasdaq: ZEAL) announced that the FDA granted Fast Track Designation for their investigational GLP-1/glucagon dual agonist, BI 456906, aimed at treating non-alcoholic steatohepatitis (NASH). This designation highlights the significant unmet medical need affecting an estimated 444 million adults globally. The dual agonist is currently in a Phase II trial assessing its efficacy in adults with NASH and liver fibrosis. The collaboration aims to leverage both companies' strengths in developing innovative therapies for cardiometabolic diseases.
Zealand Pharma (NASDAQ: ZEAL) announced its total number of shares and voting rights as of May 31, 2021, following the exercise of employee warrants. The total number of shares stands at 43,451,842, with a corresponding share capital of 43,451,842 DKK. This update is part of a compliance requirement under the Danish Capital Markets Act. Zealand continues to focus on innovative peptide-based medicines, with a pipeline that includes several candidates in late-stage development and ongoing collaborations with major pharmaceutical partners.
Zealand Pharma (Nasdaq: ZEAL) announced transactions involving its shares by managerial personnel and their close associates. This disclosure is part of the company's regulatory requirements. The company focuses on developing peptide-based medicines, with more than 10 drug candidates in clinical development, including the recently FDA-approved Zegalogue for severe hypoglycemia. Zealand's pipeline also includes several late-stage candidates and collaborations with major pharmaceutical companies.
Zealand Pharma has launched a new long-term incentive program (LTIP) for its US-based corporate management, aligning with their remuneration policy. The program includes 32,363 restricted stock units (RSUs) and 97,090 performance stock units (PSUs), aimed at enhancing performance and retaining top talent. The RSUs vest annually over three years, while the PSUs vest based on operational and market-based performance goals. The estimated value of the share-based remuneration is DKK 24.8 million, with no dilution effect on shareholders due to the use of treasury shares.
Zealand Pharma will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. Senior management will present insights into the company's innovative peptide-based medicines, aiming to transform patient lives. The event will be accessible via a live webcast on Zealand's investor relations page, with a replay available shortly after. Zealand Pharma is focused on developing treatments for diabetes, including V-Go® and Zegalogue®, showcasing a strong pipeline with multiple candidates in clinical stages.